

The English translation is an unofficial translation and in the event of a conflict between the English and the Swedish text versions, the Swedish text version shall prevail.

PROPOSALS FOR RESOLUTIONS FROM THE NOMINATION COMMITTEE OF GLOBAL HEALTH PARTNER TO THE ANNUAL GENERAL MEETING 2009

The nomination committee of Global Health Partner

At an extraordinary general meeting on 16 September 2008, it was decided that Global Health Partner shall have a nomination committee of four members, comprising of the Chairman of the Board and one representative from each of the three main shareholders in terms of votes as of 1 November 2008.

At the inaugural meeting of the nomination committee Thomas Eklund, Investor AB, was elected Chairman. The other representatives are Thomas Eriksson, Metroland BV and Andrew Wilson, Hosar Ltd. As the chairman of the Board of Directors, Urban Jansson is also a member of the nomination committee.

Election of the Chairman of the Meeting (item 2 of the agenda)

The Nomination Committee's proposal is that Urban Jansson is elected chairman of the Annual General Meeting.

Determination of fees to the Board of Directors and the Auditor (agenda item 11)

The Nomination Committee's proposes a yearly remuneration to the board members according to the following:

- 400,000 SEK to the chairman of the board
- 200,000 SEK to other board member (1) who is not employed and not representing main owner
- 150,000 SEK to other board members (2) who are no employed but representing main owners
- No remuneration to board member who is employed by Global Health Partner

No further remuneration is paid for committee work.

The nomination committee proposes that the Auditor's fee until the next AGM, be paid on approved account. Ernst & Young, and the authorized auditor Sven-Arne Gårdh as responsible auditor, was elected at the AGM 2008 for a period of four years.

Proposal for resolution on number of Directors and election of Board of Directors (agenda items 10 and 12)

The Nomination Committee proposes that the Board of Directors shall comprise of five members with no deputy members.

The Nomination Committee proposes re-election of Urban Jansson, Andrew Wilson, Lottie Svedenstedt and Per Båtelson, and a new-election of Karl Swartling, for a period until the next Annual General Meeting. The Nomination Committee proposes that the present chairman Urban Jansson shall remain chairman of the board. Joachim Werr has resigned from the Board of Directors.

Motivation for choice of Board of Directors

Karl Swartling is Managing Director and Co-Head of Investor Growth Capital Europe (Stockholm). He joined the company in January 2004. Before joining the Stockholm office, Karl spent 15 years with the McKinsey & Company consulting firm. During his last seven years at McKinsey, Karl was a partner in the company's Stockholm office. As a consultant, he focused on two main industry sectors: life sciences and industry. Karl also led McKinsey's Scandinavian Life Sciences Practice for a period of five years. Karl holds an M.B.A. from the Stockholm School of Economics.

The English translation is an unofficial translation and in the event of a conflict between the English and the Swedish text versions, the Swedish text version shall prevail.

Karl Swartling is independent from the company and the management but not from the main owners of the company. Karl Swartling and his related parties do not own any Global Health Partner shares.

An evaluation and assessment of the Board was made ahead of the change of the listing from AIM in London to NASDAQ OMX Stockholm. Based on that, some changes were made to reflect identified expectations and demands. Ahead of the Annual General Meeting, the Nomination Committee has made an assessment and evaluation of the demands that will be put on the Board based on the business of the Company, including discussions around the size of the Board, its composition, relevant experience and competence.

It is the view of the Nomination Committee that the current Board has worked well and handled its responsibilities to satisfaction, and that Karl Swartling will add relevant competence and experience.

Furthermore, it is the view of the Nomination Committee that the proposed Board is compliant with the regulations of the Swedish Code of Corporate Governance and the NASDAQ OMX Stockholm regulations.

The nomination committee's proposal on resolution on nomination committee work for the AGM 2010 (item 15 on the agenda)

The nomination committee proposes that the Annual General Meeting shall decide the following concerning a nomination committee for the AGM 2010:

Global Health Partner shall have a nomination committee consisting of the Chairman of the Board and one representative from each of the three largest owners. If any of these three do not wish to elect a representative, this right is passed to the fourth largest owner, etc. The names of the three representatives and the shareholders they represent shall be made public no later than 6 months ahead of the 2010 AGM. The nomination committee's mandate is valid until that a new committee has been elected. If nothing else is decided by the committee members, the member representing the largest owner shall be the chairman.

The nomination committee shall be inaugurated based on ownership statistic from Euroclear Sweden AB (previously VPC AB) as of the last day of September 2009.

The nomination committee shall present proposals regarding the following items to be presented before the 2010 AGM:

- 1) Chairman at the AGM,
- 2) Number of Board members,
- 3) Board of Directors,
- 4) Chairman of the board,
- 5) Fees to Board of Directors and remuneration for committee work,
- 6) Fees to group auditors,
- 7) When applicable, election of auditor, and
- 8) Proposal for resolution on election committee ahead of the AGM 2011.

In addition, the election committee shall fulfil all possible tasks following the Swedish Code of Corporate Governance.

The Election Committee in March 2009